Essex Bio-Technology (HKSE:01061) Total Receivables: HK$741 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01061 Essex Bio-Technology Ltd HKSE:01061
86 GF Score
Price HK$2.29
GF Value HK$3.13
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Essex Bio-Technology Total Receivables?

Essex Bio-Technology HKSE:01061 +0.88% 86 Total Receivables is HK$741 Mil as of Jun. 2026. GuruFocus rates HKSE:01061 with a GF Score™ of 86/100 and a GF Value™ of HK$3.13 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Essex Bio-Technology's Total Receivables for the quarter that ended in Jun. 2026 was HK$741 Mil.

Essex Bio-Technology Total Receivables Related Terms

Essex Bio-Technology Total Receivables Historical Data

* Premium members only.

The historical data trend for Essex Bio-Technology's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Essex Bio-Technology Total Receivables Chart

Essex Bio-Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 714.25 500.06 637.24 617.02 707.63

Essex Bio-Technology Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 695.58 617.02 691.90 707.63 740.97
HKSE:01061
86GF Score
Essex Bio-Technology Ltd HKSE:01061
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Essex Bio-Technology Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of HK$741 Mil mean?
Essex Bio-Technology (HKSE:01061) has a Total Receivables of HK$741 Mil as of Jun. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Essex Bio-Technology and its competitors.
Is Essex Bio-Technology's Total Receivables too high?
Essex Bio-Technology's current Total Receivables is HK$741 Mil. Overall, Essex Bio-Technology has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Essex Bio-Technology's Total Receivables compare to ZTS?
Essex Bio-Technology's Total Receivables of HK$741 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Essex Bio-Technology and its competitors. Essex Bio-Technology's current Total Receivables is HK$741 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Essex Bio-Technology stock overvalued right now?
Based on GuruFocus' analysis, Essex Bio-Technology (HKSE:01061) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.13, compared to a current price of HK$2.29 — trading 26.8% below its estimated fair value. The current Total Receivables is HK$741 Mil. Essex Bio-Technology's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Essex Bio-Technology (HKSE:01061), the current Total Receivables is HK$741 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Essex Bio-Technology (HKSE:01061) Overvalued in 2026?

Based on GuruFocus' analysis, Essex Bio-Technology stock appears to be undervalued. The current stock price of HK$2.29 is trading 26.8% below its estimated GF Value™ of HK$3.13. GuruFocus considers Essex Bio-Technology to be Modestly Undervalued.

Key valuation signals for HKSE:01061:

  • Total Receivables: HK$741 Mil
  • GF Value™: HK$3.13 vs. price of HK$2.29 (26.8% below fair value)
  • GF Score™: 86/100 with 3 warning signs

No single metric tells the full story. See the HKSE:01061 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Essex Bio-Technology Business Description

Address No. 88, Keji 6th Road, Hi-Tech Zone, Guangdong, Zhuhai, CHN
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture, and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, and Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel, and mouthwash. The majority of the group's revenue comes from the PRC, also operates in Hong Kong and other countries.
86GF Score

Get the complete analysis for HKSE:01061

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.29
Price
HK$3.13
GF Value